MedTrace Logo

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

NCT04672499 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-12-17

No results posted yet for this study

Summary

This study will assess the safety, tolerability, and pharmacokinetics (PK) of miricorilant (CORT118335) tablet formulations following single and multiple oral administration in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

Miricorilant 300 mg tablets

Miricorilant 300 mg tablets for oral administration

DRUG

Miricorilant 150 mg tablets

Miricorilant 150 mg tablets for oral administration

DRUG

Placebo 150 mg tablets

Placebo to match miricorilant 150 mg tablets for oral administration

Sponsors & Collaborators

  • Corcept Therapeutics

    lead INDUSTRY

Principal Investigators

  • Sharan Sidhu, MBChB, BAO, MRCS, MFPM · Quotient Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-27
Primary Completion
2020-09-07
Completion
2020-09-07
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04672499 on ClinicalTrials.gov